Volociximab in cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 2, 2012, Pages 251-257

  Almokadem, Salah ^a   Belani, Chandra P ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

5 1 integrin; Angiogenesis; Integrin; Volociximab

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; DOXORUBICIN; FIBRONECTIN; GEMCITABINE; PACLITAXEL; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPONATREMIA; INTESTINE OBSTRUCTION; KIDNEY CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; REVIEW; SMALL INTESTINE OBSTRUCTION; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; CLINICAL TRIALS, PHASE II AS TOPIC; FIBRONECTINS; HUMANS; INTEGRIN ALPHA5BETA1; NEOPLASMS;

EID: 84855685421     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.646985     Document Type: Review

References (40)

1. Abumiya T, Lucero J, Heo JH, et al. Activated microvessels express vascular endothelial growth factor and integrin alphavbeta3 during focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:1038-50 (Pubitemid 30173727)
2. Freije JM, Balbin M, Pendas AM, et al. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107 (Pubitemid 37176782)
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
4. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16 (Pubitemid 37361786)
5. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87 (Pubitemid 35283958)
6. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516-23 (Pubitemid 44332916)
7. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68 (Pubitemid 40064899)
8. Francis SE, Goh KL, Hodivala-Dilke K, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002;22:927-33 (Pubitemid 34655219)
9. Robinson EE, Foty RA, Corbett SA. Fibronectin matrix assembly regulates alpha5beta1-mediated cell cohesion. Mol Biol Cell 2004;15:973-81 (Pubitemid 38316208)
10. Yang JT, Rayburn H, Hynes RO. Embryonic mesodermal defects in alpha5 integrin-deficient mice. Development 1993;119:1093-105 (Pubitemid 23358579)
11. Kim S, Harris M, Varner JA. Regulation of integrin alphavbeta3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000;275:33920-8
12. Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser- Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994;269:24756-61 (Pubitemid 24311733)
13. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62 (Pubitemid 30660012)
14. Beauvais A, Erickson CA, Goins T, et al. Changes in the fibronectin-specific integrin expression pattern modify the migratory behavior of sarcoma S180 cells in vitro and in the embryonic environment. J Cell Biol 1995;128:699-713
15. Gong J, Wang D, Sun L, et al. Role of alpha5beta1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997;8:83-90 (Pubitemid 27030241)
16. Qian F, Zhang ZC, Wu XF, et al. Interaction between integrin alpha5 and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun 2005;333:1269-75 (Pubitemid 40910139)
17. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alphavbeta3 for angiogenesis. Science 1994;264:569-71
18. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 1999;112:569-78 (Pubitemid 29106203)
19. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305 (Pubitemid 26231000)
20. Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis. J Biol Chem 2004;279:4862-8 (Pubitemid 38199081)
21. Kim S, Bakre M, Yin H, Varner JA. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002;110:933-41
22. Barkan D, Chambers AF. beta1-integrin: A potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011;17:7219-23
23. Ramakrishnan V, Bhaskar V, Law DA, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006;5:273-86 (Pubitemid 44497002)
24. Ricart AD, Tolcher AW, Liu G, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: A Phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-9
25. Stephenson JJ, Cranmer L, Hodi S, et al. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. J Clin Oncol 2008;26 (20 Suppl):abstract 9051
26. Cranmer LD, Bedikian AY, Ribas A, et al. Phase II study of volociximab (M200), an alpha5beta1 anti-integrin antibody in metastatic melanoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24 (18 Suppl 20):8011
27. Evans T, Valle J, Berlin J, et al. Ramanathan Interim results from a phase II study of volociximab in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer [abstract # 142]. 2008 ASCO Gastrointesintal Cancer Symposium
28. Evans T, Ramanathan RK, Yazji S, et al. Final results from cohort 1 of a phase II study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18 Suppl 20):4549
29. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32
30. Figlin RA, Kondagunta GV, Yazji S, et al. Phase II study of volociximab (M200), an alpha5beta1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24 (18 Suppl 20):4535
31. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an alpha5beta1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 (18 Suppl 20):5094
32. Markowska J, Szala S. Inhibitors of angiogenesis in therapy of ovarian cancers. Eur J Gynaecol Oncol 2004;25:562-7 (Pubitemid 39287112)
33. Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995;91:229-34
34. Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-39 (Pubitemid 351521807)
35. Bell-McGuinn KM, Matthews CM, Ho SN, et al. A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273-9
36. Vergote IB, Colombo N, Kutarska E, et al. Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2009;27 (15 Suppl):abstract 5560
37. Adachi M, Taki T, Higashiyama M, et al. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101 (Pubitemid 30064981)
38. Han JY, Kim HS, Lee SH, et al. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003;41:65-70 (Pubitemid 36765485)
39. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
40. Besse B, Soria JC, Chico I, et al. Volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2009;7 (2 Suppl):547